Cross reactive antigenicity in orally vaccinated foxes and raccoon dogs against European Bat Lyssavirus type 1 and 2.
Identifieur interne : 000233 ( PubMed/Checkpoint ); précédent : 000232; suivant : 000234Cross reactive antigenicity in orally vaccinated foxes and raccoon dogs against European Bat Lyssavirus type 1 and 2.
Auteurs : T. Müller [Allemagne] ; T. Selhorst ; J. Burow ; A. Schameitat ; A. VosSource :
- Developments in biologicals [ 1424-6074 ] ; 2006.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (immunology), Cross Reactions, Ferrets (immunology), Ferrets (virology), Foxes (immunology), Foxes (virology), Lyssavirus (immunology), Rabies Vaccines (administration & dosage), Rabies Vaccines (immunology), Raccoon Dogs (immunology), Raccoon Dogs (virology), Rhabdoviridae Infections (immunology), Rhabdoviridae Infections (prevention & control), Species Specificity, Vaccines, Attenuated (administration & dosage), Vaccines, Attenuated (immunology).
- MESH :
- chemical , administration & dosage : Rabies Vaccines, Vaccines, Attenuated.
- chemical , immunology : Antibodies, Viral, Rabies Vaccines, Vaccines, Attenuated.
- immunology : Ferrets, Foxes, Lyssavirus, Raccoon Dogs, Rhabdoviridae Infections.
- prevention & control : Rhabdoviridae Infections.
- virology : Ferrets, Foxes, Raccoon Dogs.
- Animals, Cross Reactions, Species Specificity.
Abstract
For the first time, the effectiveness of oral rabies vaccines against European Bat Lyssaviruses Type 1 (EBLV-1) and Type 2 (EBLV-2) by means of cross-neutralization assays was investigated. Sera from orally vaccinated red foxes (Vulpes vulpes) and raccoon dogs (Nyctereutes procyonoides) with the Street Alabama Dufferin (SAD) B19 and SAD P5/88 live-modified vaccine viruses were used to study the cross reactive antigenicity against CVS-11 (genotype 1), EBLV-1 (genotype 5) and EBLV-2 (genotype 6). For comparison, similar crossneutralization assays with sera from EBLV-1 and EBLV-2 infected ferrets (Mustela putorius furo) and/or foxes were conducted. Sera from animals vaccinated with the two oral rabies vaccines were reactive against CVS-11 (homologous virus), EBLV-1 and EBLV-2 (heterologous virus). There was a positive relationship among the virus neutralising antibody titres (VNA); high VNA titres against CVS-11 also resulted in high VNA titres against each EBLV, whereas in general, the VNA-titres obtained with homologous virus were statistically higher than those with the heterologous virus except for SAD P5/88 vaccinated raccoon dogs. No significant difference was found between EBLV-1 and EBLV-2 VNA titres. A similar trend was observed when the results of the cross-neutralization data of the foxes and ferrets inoculated i.m. with EBLV-1 and/or EBLV-2 was analysed. Based on the similarity of the EBLV-VNA titres obtained in our study questions were raised on whether the genetic distance of genotype 5 & 6 within phylogroup 1 really does reflect their antigenetic characteristics or whether this is a feature of attenuated live vaccine viruses. This broad cross protection, however, demonstrated that the representatives of attenuated SAD strains of oral rabies vaccines currently used in Germany are most likely able to protect the reservoir species, red fox and raccoon dog, against EBLV-1 and EBLV-2 infection.
PubMed: 16878477
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:16878477Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cross reactive antigenicity in orally vaccinated foxes and raccoon dogs against European Bat Lyssavirus type 1 and 2.</title><author><name sortKey="Muller, T" sort="Muller, T" uniqKey="Muller T" first="T" last="Müller">T. Müller</name><affiliation wicri:level="1"><nlm:affiliation>Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, WHO Collaborating Centre for Rabies Surveillance and Research, Wusterhausen, Germany. thomas.mueller@fli.bund.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, WHO Collaborating Centre for Rabies Surveillance and Research, Wusterhausen</wicri:regionArea><wicri:noRegion>Wusterhausen</wicri:noRegion><wicri:noRegion>Wusterhausen</wicri:noRegion><wicri:noRegion>Wusterhausen</wicri:noRegion></affiliation></author><author><name sortKey="Selhorst, T" sort="Selhorst, T" uniqKey="Selhorst T" first="T" last="Selhorst">T. Selhorst</name></author><author><name sortKey="Burow, J" sort="Burow, J" uniqKey="Burow J" first="J" last="Burow">J. Burow</name></author><author><name sortKey="Schameitat, A" sort="Schameitat, A" uniqKey="Schameitat A" first="A" last="Schameitat">A. Schameitat</name></author><author><name sortKey="Vos, A" sort="Vos, A" uniqKey="Vos A" first="A" last="Vos">A. Vos</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16878477</idno><idno type="pmid">16878477</idno><idno type="wicri:Area/PubMed/Corpus">000241</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000241</idno><idno type="wicri:Area/PubMed/Curation">000241</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000241</idno><idno type="wicri:Area/PubMed/Checkpoint">000241</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000241</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cross reactive antigenicity in orally vaccinated foxes and raccoon dogs against European Bat Lyssavirus type 1 and 2.</title><author><name sortKey="Muller, T" sort="Muller, T" uniqKey="Muller T" first="T" last="Müller">T. Müller</name><affiliation wicri:level="1"><nlm:affiliation>Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, WHO Collaborating Centre for Rabies Surveillance and Research, Wusterhausen, Germany. thomas.mueller@fli.bund.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, WHO Collaborating Centre for Rabies Surveillance and Research, Wusterhausen</wicri:regionArea><wicri:noRegion>Wusterhausen</wicri:noRegion><wicri:noRegion>Wusterhausen</wicri:noRegion><wicri:noRegion>Wusterhausen</wicri:noRegion></affiliation></author><author><name sortKey="Selhorst, T" sort="Selhorst, T" uniqKey="Selhorst T" first="T" last="Selhorst">T. Selhorst</name></author><author><name sortKey="Burow, J" sort="Burow, J" uniqKey="Burow J" first="J" last="Burow">J. Burow</name></author><author><name sortKey="Schameitat, A" sort="Schameitat, A" uniqKey="Schameitat A" first="A" last="Schameitat">A. Schameitat</name></author><author><name sortKey="Vos, A" sort="Vos, A" uniqKey="Vos A" first="A" last="Vos">A. Vos</name></author></analytic><series><title level="j">Developments in biologicals</title><idno type="ISSN">1424-6074</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (immunology)</term><term>Cross Reactions</term><term>Ferrets (immunology)</term><term>Ferrets (virology)</term><term>Foxes (immunology)</term><term>Foxes (virology)</term><term>Lyssavirus (immunology)</term><term>Rabies Vaccines (administration & dosage)</term><term>Rabies Vaccines (immunology)</term><term>Raccoon Dogs (immunology)</term><term>Raccoon Dogs (virology)</term><term>Rhabdoviridae Infections (immunology)</term><term>Rhabdoviridae Infections (prevention & control)</term><term>Species Specificity</term><term>Vaccines, Attenuated (administration & dosage)</term><term>Vaccines, Attenuated (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Rabies Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Rabies Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Ferrets</term><term>Foxes</term><term>Lyssavirus</term><term>Raccoon Dogs</term><term>Rhabdoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Rhabdoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Ferrets</term><term>Foxes</term><term>Raccoon Dogs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cross Reactions</term><term>Species Specificity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">For the first time, the effectiveness of oral rabies vaccines against European Bat Lyssaviruses Type 1 (EBLV-1) and Type 2 (EBLV-2) by means of cross-neutralization assays was investigated. Sera from orally vaccinated red foxes (Vulpes vulpes) and raccoon dogs (Nyctereutes procyonoides) with the Street Alabama Dufferin (SAD) B19 and SAD P5/88 live-modified vaccine viruses were used to study the cross reactive antigenicity against CVS-11 (genotype 1), EBLV-1 (genotype 5) and EBLV-2 (genotype 6). For comparison, similar crossneutralization assays with sera from EBLV-1 and EBLV-2 infected ferrets (Mustela putorius furo) and/or foxes were conducted. Sera from animals vaccinated with the two oral rabies vaccines were reactive against CVS-11 (homologous virus), EBLV-1 and EBLV-2 (heterologous virus). There was a positive relationship among the virus neutralising antibody titres (VNA); high VNA titres against CVS-11 also resulted in high VNA titres against each EBLV, whereas in general, the VNA-titres obtained with homologous virus were statistically higher than those with the heterologous virus except for SAD P5/88 vaccinated raccoon dogs. No significant difference was found between EBLV-1 and EBLV-2 VNA titres. A similar trend was observed when the results of the cross-neutralization data of the foxes and ferrets inoculated i.m. with EBLV-1 and/or EBLV-2 was analysed. Based on the similarity of the EBLV-VNA titres obtained in our study questions were raised on whether the genetic distance of genotype 5 & 6 within phylogroup 1 really does reflect their antigenetic characteristics or whether this is a feature of attenuated live vaccine viruses. This broad cross protection, however, demonstrated that the representatives of attenuated SAD strains of oral rabies vaccines currently used in Germany are most likely able to protect the reservoir species, red fox and raccoon dog, against EBLV-1 and EBLV-2 infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16878477</PMID><DateCreated><Year>2006</Year><Month>08</Month><Day>01</Day></DateCreated><DateCompleted><Year>2006</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2006</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1424-6074</ISSN><JournalIssue CitedMedium="Print"><Volume>125</Volume><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Developments in biologicals</Title><ISOAbbreviation>Dev Biol (Basel)</ISOAbbreviation></Journal><ArticleTitle>Cross reactive antigenicity in orally vaccinated foxes and raccoon dogs against European Bat Lyssavirus type 1 and 2.</ArticleTitle><Pagination><MedlinePgn>195-204</MedlinePgn></Pagination><Abstract><AbstractText>For the first time, the effectiveness of oral rabies vaccines against European Bat Lyssaviruses Type 1 (EBLV-1) and Type 2 (EBLV-2) by means of cross-neutralization assays was investigated. Sera from orally vaccinated red foxes (Vulpes vulpes) and raccoon dogs (Nyctereutes procyonoides) with the Street Alabama Dufferin (SAD) B19 and SAD P5/88 live-modified vaccine viruses were used to study the cross reactive antigenicity against CVS-11 (genotype 1), EBLV-1 (genotype 5) and EBLV-2 (genotype 6). For comparison, similar crossneutralization assays with sera from EBLV-1 and EBLV-2 infected ferrets (Mustela putorius furo) and/or foxes were conducted. Sera from animals vaccinated with the two oral rabies vaccines were reactive against CVS-11 (homologous virus), EBLV-1 and EBLV-2 (heterologous virus). There was a positive relationship among the virus neutralising antibody titres (VNA); high VNA titres against CVS-11 also resulted in high VNA titres against each EBLV, whereas in general, the VNA-titres obtained with homologous virus were statistically higher than those with the heterologous virus except for SAD P5/88 vaccinated raccoon dogs. No significant difference was found between EBLV-1 and EBLV-2 VNA titres. A similar trend was observed when the results of the cross-neutralization data of the foxes and ferrets inoculated i.m. with EBLV-1 and/or EBLV-2 was analysed. Based on the similarity of the EBLV-VNA titres obtained in our study questions were raised on whether the genetic distance of genotype 5 & 6 within phylogroup 1 really does reflect their antigenetic characteristics or whether this is a feature of attenuated live vaccine viruses. This broad cross protection, however, demonstrated that the representatives of attenuated SAD strains of oral rabies vaccines currently used in Germany are most likely able to protect the reservoir species, red fox and raccoon dog, against EBLV-1 and EBLV-2 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, WHO Collaborating Centre for Rabies Surveillance and Research, Wusterhausen, Germany. thomas.mueller@fli.bund.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selhorst</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Burow</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schameitat</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vos</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dev Biol (Basel)</MedlineTA><NlmUniqueID>100940058</NlmUniqueID><ISSNLinking>1424-6074</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011819">Rabies Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005589" MajorTopicYN="N">Foxes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018114" MajorTopicYN="N">Lyssavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011819" MajorTopicYN="N">Rabies Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046031" MajorTopicYN="N">Raccoon Dogs</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018353" MajorTopicYN="N">Rhabdoviridae Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16878477</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Burow, J" sort="Burow, J" uniqKey="Burow J" first="J" last="Burow">J. Burow</name><name sortKey="Schameitat, A" sort="Schameitat, A" uniqKey="Schameitat A" first="A" last="Schameitat">A. Schameitat</name><name sortKey="Selhorst, T" sort="Selhorst, T" uniqKey="Selhorst T" first="T" last="Selhorst">T. Selhorst</name><name sortKey="Vos, A" sort="Vos, A" uniqKey="Vos A" first="A" last="Vos">A. Vos</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Muller, T" sort="Muller, T" uniqKey="Muller T" first="T" last="Müller">T. Müller</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Bois/explor/RenardV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000233 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000233 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Bois
|area= RenardV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:16878477
|texte= Cross reactive antigenicity in orally vaccinated foxes and raccoon dogs against European Bat Lyssavirus type 1 and 2.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:16878477" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a RenardV1
| This area was generated with Dilib version V0.6.27. |  |